Prospera Financial Services Inc decreased its position in Sanofi (NYSE:SNY) by 6.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,168 shares of the company’s stock after selling 425 shares during the period. Prospera Financial Services Inc’s holdings in Sanofi were worth $258,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of SNY. JFS Wealth Advisors LLC increased its position in Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock worth $166,000 after buying an additional 134 shares during the last quarter. BlackRock Institutional Trust Company N.A. bought a new stake in shares of Sanofi during the first quarter worth $175,000. Rehmann Capital Advisory Group increased its stake in shares of Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock worth $233,000 after buying an additional 26 shares during the last quarter. Flow Traders U.S. LLC increased its stake in shares of Sanofi by 1.3% in the first quarter. Flow Traders U.S. LLC now owns 6,128 shares of the company’s stock worth $246,000 after buying an additional 81 shares during the last quarter. Finally, Cypress Wealth Advisors LLC bought a new stake in shares of Sanofi during the first quarter worth $247,000. 9.42% of the stock is currently owned by institutional investors and hedge funds.
Shares of Sanofi (NYSE:SNY) traded down 0.57% on Friday, hitting $38.35. The stock had a trading volume of 1,086,862 shares. The firm has a market cap of $98.71 billion, a PE ratio of 21.22 and a beta of 1.01. Sanofi has a 52-week low of $37.41 and a 52-week high of $51.88. The firm’s 50-day moving average price is $39.29 and its 200 day moving average price is $40.61.
SNY has been the topic of a number of recent research reports. TheStreet raised Sanofi from a “hold” rating to a “buy” rating in a research report on Wednesday, July 27th. Berenberg Bank raised Sanofi from a “hold” rating to a “buy” rating in a research report on Thursday, September 8th. Zacks Investment Research raised Sanofi from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. Jefferies Group reaffirmed a “hold” rating on shares of Sanofi in a research report on Wednesday, September 14th. Finally, BNP Paribas raised Sanofi from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. Sanofi presently has an average rating of “Hold” and an average target price of $60.50.
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.